Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b alisertib + weekly paclitaxel in East Asian patients with advanced solid tumors
jRCT2080222793Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of alisertib in advanced nonhematological malignancy, ovarian cancer and small cell lung cancer (SCLC) (2 cohorts), sponsored by Takeda. Primary endpoints: Maximum tolerated dose (MTD) of alisertib in combination with weekly paclitaxel and Dose-limiting toxicities (DLTs) of alisertib + paclitaxel. Started Mar 2015; status: completed.
02
Drugs
alisertib
03
Conditions
advanced nonhematological malignancyovarian cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080222793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222793.